argenx (ARGX) Q2 2024 earnings summary

Executive summary

• Q2 2024 product net sales reached $478M, a 78% year-over-year increase and 20% sequential growth, driven by VYVGART and VYVGART Hytrulo, with US sales at $407M and all MG patients; CIDP and ITP approvals expanded the addressable market.

• Vision 2030 targets 50,000 patients globally, 10 labeled indications, and 5 molecules in phase III, with continued expansion in MG, CIDP, and new indications leveraging a robust innovation pipeline.

• VYVGART approved in multiple regions and indications, with significant regulatory milestones and global launches expected in 2024-2025.

• Pipeline includes efgartigimod in 15 indications, empasiprubart in four, and ARGX-119 in CMS and ALS.

Financial highlights

• Q2 2024 total operating income was $489M, up from $281M in Q2 2023; H1 2024 operating income reached $902M, up from $511M in H1 2023.

• Product net sales: Q2 2024 $478M (U.S.: $407M, Japan: $20M, EMEA: $35M, China: $14M); H1 2024 $876M.

• Operating expenses: Q2 2024 $535M, H1 2024 $1,041M, mainly due to higher R&D and SG&A costs.

• Net profit for Q2 2024 was $29M, compared to a net loss of $94M in Q2 2023; H1 2024 net loss narrowed to $33M.

• Cash, cash equivalents, and current financial assets totaled $3.1B as of June 30, 2024.

Outlook and guidance

• Expect continued growth in MG and initial CIDP revenues in Q3; multiple phase III studies to start before year-end, including TED, Sjögren's, and MMN.

• No revenue guidance for 2024 due to CIDP and geographic expansion uncertainties; expense and cash guidance maintained, with 2024 cash burn expected to be less than $0.5B.

• Combined R&D and SG&A expenses for 2024 projected to be under $2.0B; R&D and SG&A expected to remain elevated to support pipeline and commercialization.

• Plans to reach earlier-line MG patients in next 12-18 months with label expansions and pre-filled syringe.